Press Releases Amarantus Enters into Exclusive Op
Post# of 30028
(Total Views: 470)
Posted On: 05/04/2018 9:08:24 AM
Press Releases
Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test vs. Amyloid PET
Download as PDF
MAY 04, 2018
NEW YORK, May 04, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that it has entered into an exclusive option agreement with Leipzig University. The exclusive option agreement allows the Company to license rights to "LymPro Test 2.0" which incorporates LymPro Test results with those of amyloid PET imaging for the diagnosis of Alzheimer's disease.
Under the terms of the agreement, Amarantus acquired an exclusive option to evaluate data produced from a German-based clinical study (LymPro PET 1) initiated in 2016 and completed in 2017 under the supervision of Dr. Thomas Arendt, the inventor of LymPro Test. Amarantus received a summary of the data on May 2, 2018. Upon exercising the Company's exclusive option, Amarantus and Leipzig will complete negotiations to license LymPro IP and data created from LymPro PET 1 to Amarantus, and collaborate on a confirmatory 20 subject trial (LymPro PET 2) currently enrolling under Dr. Arendt's supervision.
AAIC 2015 Poster Presentation of LymPro Test LP-002 Clinical Data
Amarantus Alzheimer's Diagnostics Scientific Advisory Board
Dr. Ropacki Appointed Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test
Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test vs. Amyloid PET
Download as PDF
MAY 04, 2018
NEW YORK, May 04, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that it has entered into an exclusive option agreement with Leipzig University. The exclusive option agreement allows the Company to license rights to "LymPro Test 2.0" which incorporates LymPro Test results with those of amyloid PET imaging for the diagnosis of Alzheimer's disease.
Under the terms of the agreement, Amarantus acquired an exclusive option to evaluate data produced from a German-based clinical study (LymPro PET 1) initiated in 2016 and completed in 2017 under the supervision of Dr. Thomas Arendt, the inventor of LymPro Test. Amarantus received a summary of the data on May 2, 2018. Upon exercising the Company's exclusive option, Amarantus and Leipzig will complete negotiations to license LymPro IP and data created from LymPro PET 1 to Amarantus, and collaborate on a confirmatory 20 subject trial (LymPro PET 2) currently enrolling under Dr. Arendt's supervision.
AAIC 2015 Poster Presentation of LymPro Test LP-002 Clinical Data
Amarantus Alzheimer's Diagnostics Scientific Advisory Board
Dr. Ropacki Appointed Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test
(4)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼